Skip to Content

Titan Pharmaceuticals Inc TTNP

Morningstar Rating
$7.26 +0.10 (1.40%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TTNP is trading at a 68% discount.
Price
$7.22
Fair Value
$27.98
Uncertainty
Extreme
1-Star Price
$934.22
5-Star Price
$5.26
Economic Moat
Vcmbf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TTNP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$7.16
Day Range
$6.987.26
52-Week Range
$5.0016.60
Bid/Ask
$6.97 / $7.27
Market Cap
$6.64 Mil
Volume/Avg
3,774 / 12,089

Key Statistics

Price/Earnings (Normalized)
Price/Sales
5,518.80
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
4

Valuation

Metric
TTNP
Price/Earnings (Normalized)
Price/Book Value
0.86
Price/Sales
5,518.80
Price/Cash Flow
Price/Earnings
TTNP

Financial Strength

Metric
TTNP
Quick Ratio
5.41
Current Ratio
5.55
Interest Coverage
Quick Ratio
TTNP

Profitability

Metric
TTNP
Return on Assets (Normalized)
−125.60%
Return on Equity (Normalized)
−213.35%
Return on Invested Capital (Normalized)
−192.24%
Return on Assets
TTNP
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRZmhdvtfdpQqwx$564.6 Bil
REGN
Regeneron Pharmaceuticals IncBpyfjtmdMtpcx$102.8 Bil
VRTX
Vertex Pharmaceuticals IncTtlnddrrTlzffwv$102.5 Bil
MRNA
Moderna IncHlyymynyXdzwh$41.0 Bil
ARGX
argenx SE ADRDjrcwjqzDgmg$22.8 Bil
BNTX
BioNTech SE ADRGfwbvgfnpGkgm$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncXmdbxvssfYjtlbm$18.8 Bil
BMRN
Biomarin Pharmaceutical IncBmwhclchpWkvcsq$17.4 Bil
RPRX
Royalty Pharma PLC Class AGqzggknbnSsctb$12.6 Bil
INCY
Incyte CorpHtwgbfxvXcdzj$12.1 Bil

Sponsor Center